Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) EBT: 2021-2024

Historic EBT for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$302.1 million.

  • Amylyx Pharmaceuticals' EBT rose 52.70% to -$34.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.9 million, marking a year-over-year increase of 41.78%. This contributed to the annual value of -$302.1 million for FY2024, which is 656.45% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its EBT stood at -$302.1 million for FY2024, which was down 656.45% from $54.3 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' EBT registered a high of $54.3 million during FY2023, and its lowest value of -$302.1 million during FY2024.
  • Over the past 3 years, Amylyx Pharmaceuticals' median EBT value was -$198.7 million (recorded in 2022), while the average stood at -$148.8 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' EBT spiked by 127.33% in 2023 and then slumped by 656.45% in 2024.
  • Yearly analysis of 4 years shows Amylyx Pharmaceuticals' EBT stood at -$87.9 million in 2021, then slumped by 125.98% to -$198.7 million in 2022, then spiked by 127.33% to $54.3 million in 2023, then slumped by 656.45% to -$302.1 million in 2024.